Analyst Research Report Snapshot

Title:

MEDIVIR - BEST-IN-CLASS PI

Price:

$10.00

Provider:

Edison Investment Research

Date:

09 Jan 2013

Pages:

2

Type:

AcrobatPDF

Companies referenced:

MVIRb.ST

Available for Immediate Download
Summary:

Pivotal Phase III trials have now demonstrated Medivir’s simeprevir to be the best-in-class once daily protease inhibitor (PI) for hepatitis C (HCV). The data should ensure a rapid take up for simeprivir post approval, although partner J&J will –unusually – find itself also marketing its main competitor, Incivek (telaprevir) in the EU. Nevertheless, these data should ensure that Medivir’s drug remains in the race for the real prize, a place in the emerging all oral HCV treatment landscape.

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.